Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells.

Cancer Immunol Immunother · 2012 · PMC3249207 · PMID 21822917

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantP < 0.001actually significant

This difference was highly significant ( P < 0.001) demonstrating the importance of CD8 + effector T cells in MVA-BN ® -HER2-mediated anti-tumor efficacy.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.